The innate immune system is critical for inducing durable and protective T cell responses to
infection and has been increasingly recognized as a target for cancer immunotherapy. In this …

The innate immune pathway is receiving increasing attention in cancer therapy. This
pathway is ubiquitous across various cell types, not only in innate immune cells but also in …

Immunotherapies have revolutionized the treatment paradigms of various types of cancers.
However, most of these immunomodulatory strategies focus on harnessing adaptive …

Passive immunotherapy, including adoptive T-cell therapy and antibody therapy, has shown
encouraging results in cancer treatment lately. However, active immunotherapy of solid …

A pre-existing T cell-inflamed tumor microenvironment has prognostic utility and also can be
predictive for response to contemporary cancer immunotherapies. The generation of a …

Immunity to infectious agents involves a coordinated response of innate and adaptive
immune cells working in concert, with many feed-forward and regulatory interactions …

Tumor-infiltrating dendritic cells (DCs) correlate with effective anticancer immunity and
improved responsiveness to anti–PD-1 checkpoint immunotherapy. However, the drivers of …

Immunotherapies targeting conventional T cells have revolutionized systemic treatment for
many cancers, yet only a subset of patients benefit from these approaches. A better …

Individualized cancer therapy is a central goal of cancer biologists. Immunotherapy is a
rational means to this end—because the immune system can recognize a virtually limitless …

Chronic inflammation increases the risk of several cancers, including gastric, colon, and
hepatic cancers. Conversely, tumors, similar to tissue injury, trigger an inflammatory …